Extractas expands its medicinal cannabis capabilities for global markets
Tasmanian MPs Guy Barnett and Michael Ferguson at the opening of the new medicinal cannabis facility at Westbury in 2020. Archive photo by Mike Moores.
Extractas Bioscience, the Tasmanian pharmaceutical company originally established in Westbury as Tasmanian Alkaloids, has signed a three year partnership deal with Victorian based manufacturing company Ensign Laboratories.
As part of a reciprocal partnership, Extractas will substantially increase its medicinal cannabis formulation capacities and be a preferred supplier of medicinal cannabis APIs (active pharmaceutical ingredients) to Ensign.
Extractas has already established a reputation for reliability and quality over more than four decades.
In 2019, Extractas constructed a purpose-built, fully dedicated medicinal cannabis facility at Westbury and supplies global customers with materials for essential medicines.
Dr Ross Murdoch, Extractas CEO said, ‘With the signing of this agreement, our capacity for manufacture of finished products under GMP (good manufacturing practice) conditions exceeds 30,000 bottles per week. In combination with our extraction capacity of 90 tonnes of biomass/annum we believe that this makes us the GMP medicinal cannabis manufacturer of choice with one of the largest production capabilities in the Southern Hemisphere.
‘This is extremely positive news for the future of the industry in Tasmania and gives security to our existing staff as well as providing new employment opportunities into the future.’
